On the basis of these results, a regimen consisting of six cycles of TCHP has been the most preferred neoadjuvant treatment for HER2+ breast cancer with tumour size >2 cm or with lymph node metastasis.10 The gene discussed is ERBB2; the disease is breast cancer.